Related Experiment Video
Updated: Jan 14, 2026
Author Spotlight: Regenerative Peripheral Nerve Interface (RPNI) Surgery in Postamputation Pain Management
Published on: March 15, 2024
Perineuromal Botulinum Toxin Injection for War-Related Postamputation Pain: A Pragmatic, Multicenter, Comparative
Nadiya Segin1, Roman Smolynets2, Joana Barroso3
1Diagnostic Center of Neurological Pathology, Municipal Non-Profit Enterprise Regional Clinical Hospital of Ivano-Frankivsk Regional Council, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine.
Objectives:
To determine the comparative effectiveness of botulinum toxin (BT) injections versus comprehensive medical and surgical treatment (CMST) for war-related postamputation pain.
Design:
A prospective, comparative-effectiveness study evaluating outcomes in patients treated with BT or CMST at 2 Ukrainian hospitals.
Setting:
Two Ukrainian hospitals treating war-related injuries.
Participants:
Patients with at least 2 out of 10 residual limb pain (RLP) or phantom limb pain (PLP) were included.
Interventions:
In the BT group (N=39), patients received BT injections around neuromas in the residual limb (perineuromal), subcutaneously over sensitized tissue, and/or as trigger point injections, plus physical and pharmacotherapy as indicated. The CMST group (N=127) received injections, surgical therapies, physical and pharmacotherapies, and integrative treatments.
Main Outcome Measures:
The primary outcome measures were mean reduction in RLP and PLP at 3-month follow-up. Secondary outcome measures were RLP and PLP, and success was defined as ≥30% decrease in postamputation pain.
Results:
At 3 months, the reduction in PLP scores was greater in the CMST than the BT group (2.0±2.0 vs 3.5±3.5, P=.002). For RLP, the reduction did not differ significantly between groups (BT 2.0±2.5 vs CMST 3.0±2.8, P=.50). Conversely, the reduction in PLP at 1 month favored BT (4.0±3.5 vs 1.0±2.5, P>.001), with no significant difference in RLP reduction. Responder rates favored BT for PLP at 1 month (68.6% vs 43.1%, P=.01), and CMST for RLP (97.1% vs 63.2%, P<.001) but not PLP at 3 months.
Conclusions:
On some measures, BT outperforms or is noninferior to CMST at 1 month but not 3 months, suggesting that multimodal treatment is superior in the long term.
